Treatment of Lupus Pericarditis
For lupus pericarditis, start with NSAIDs (aspirin 750-1000 mg every 8 hours or ibuprofen 600 mg every 8 hours) plus colchicine (0.5 mg twice daily if ≥70 kg, once daily if <70 kg) for at least 3 months, with gastroprotection. 1
First-Line Treatment Approach
The ESC guidelines explicitly identify systemic inflammatory diseases (including SLE) as a specific indication for corticosteroids in pericarditis 1, but this does not mean you should start with steroids. The algorithmic approach is:
Step 1: NSAIDs + Colchicine
- Aspirin 750-1000 mg every 8 hours OR Ibuprofen 600 mg every 8 hours
- Add colchicine 0.5 mg twice daily (≥70 kg) or once daily (<70 kg) for minimum 3 months
- Always provide gastroprotection (PPI)
- Continue until symptoms resolve AND CRP normalizes (typically 1-2 weeks for NSAIDs, but colchicine continues for 3 months minimum) 1
Critical pitfall: Corticosteroids as first-line therapy increase recurrence rates up to 50% and promote chronicity 1. Even though lupus is listed as a "specific indication," the guidelines still recommend NSAIDs/colchicine first unless there are contraindications.
Step 2: Add Low-Dose Corticosteroids (If Inadequate Response)
If symptoms persist after 7 days or there is incomplete response to NSAIDs/colchicine:
- Add (not replace) prednisone 0.2-0.5 mg/kg/day to the NSAID/colchicine regimen as triple therapy 1
- Maintain initial dose until symptom resolution and CRP normalization
- Taper extremely slowly: when reaching 10-15 mg/day prednisone, decrease by only 1.0-2.5 mg every 2-6 weeks 1
- Never use high-dose steroids (≥1.0 mg/kg/day) - they worsen outcomes 1
Step 3: Refractory Disease - IL-1 Inhibition
For steroid-dependent or recurrent lupus pericarditis despite triple therapy:
- Rilonacept (IL-1 receptor antagonist) has shown remarkable efficacy in recent case series 2, 3, 4
- In the most recent 2026 case series, rilonacept achieved complete symptom resolution in 50% and partial improvement in 50% of SLE pericarditis patients, with CRP normalization in all and objective imaging improvement in 83% 2
- Allows steroid discontinuation and serves as steroid-sparing strategy 3, 4
- Consider this before B-cell targeted therapies, as one case demonstrated rilonacept success after belimumab failure 3
Monitoring and Duration
- Monitor CRP to guide treatment duration and assess response 1
- Restrict physical activity until symptoms resolve AND CRP, ECG, and echocardiogram normalize 1
- For recurrent pericarditis, extend colchicine to at least 6 months 1
- Taper one drug class at a time, only when asymptomatic with normal CRP 1
Critical Diagnostic Consideration
Before starting any immunosuppression, you must exclude infectious (septic) pericarditis, particularly in active SLE patients on immunosuppression. Recent systematic reviews show:
- Septic pericarditis in SLE is rare but rapidly fatal if missed 5, 6
- Staphylococcus aureus (including MRSA) and Salmonella species predominate 5
- Dyspnea (69%) is more common than fever (31%), and routine serologic markers cannot distinguish infection from lupus flare 5
- Low threshold for diagnostic pericardiocentesis with culture if: fever present, rapid deterioration, large effusion, or tamponade physiology 5, 6
- Consider concurrent infective endocarditis (obtain blood cultures, perform echocardiography) 6
What NOT to Do
- Do not use corticosteroids as monotherapy - always combine with NSAIDs and colchicine if used 1
- Do not use high-dose corticosteroids - they increase recurrence and chronicity 1
- Do not taper steroids quickly - this triggers recurrence 1
- Do not assume all pericardial effusions in SLE are sterile - infection can be catastrophic 5, 6
The evidence strongly supports that even in lupus pericarditis, the anti-inflammatory ladder (NSAIDs/colchicine → add low-dose steroids → IL-1 inhibition) produces better outcomes than jumping directly to corticosteroids, which the guidelines explicitly recommend against as first-line therapy 1.